Boston Scientific Q3 neuromodulation sales reach $331 million, up 13.1%
Source publication date
Site published
Boston Scientific reported Q3 2026 neuromodulation sales of US$331 million, up 13.1% year over year on a reported basis. Operational growth excluding currency effects and company-defined organic growth were both 13.0%.
The company highlighted growth across its pain portfolio and Nalu peripheral nerve stimulation (PNS). It attributed brain-business growth to the Cartesia X lead and Illumina 3D software. This is a financial update, not a new regulatory clearance or clinical-efficacy announcement. Source: https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/FOH/q3-2026-foh.pdf
Summary
The October 28 Q3 2026 presentation reports neuromodulation growth. The company highlighted its pain portfolio, particularly Nalu PNS, as a contributor.
Editorial view
The results provide a business signal for pain-related neuromodulation. One company's growth is not the growth rate of the entire pain-management market.
Evidence and limitations
Growth drivers reflect management's assessment. This source does not establish new clearances, indications, treatment efficacy or installed-unit counts. These results are not home TENS or massage-chair market data. Operational and organic growth are company-defined non-GAAP measures.